

Wellnex Life Extends Supply Agreement with Haleon

- Wellnex extends Supply Agreement with Haleon with additional products and global expansion into UK, Ireland and the UAE
- This builds on the initial Supply Agreement for Australia and New Zealand of its existing paracetamol soft gel liquid analgesic
- Haleon is a world leader in consumer health
- Validation of Wellnex's business model of being the owner of healthcare brands and IP for Australian and global markets.

Wellnex Life Limited (ASX: WNX) (Company or Wellnex) is pleased to announce it has extended its Supply Agreement (**Agreement**) with Haleon into the United Kingdom, Ireland and the United Arab Emirates (**UAE**). As announced on 18 March 2022, Wellnex signed a supply agreement for its innovative soft gel liquid paracetamol to Haleon for it to be retailed in Australia and New Zealand under Haleon's pain relief brand.

Wellnex is now pleased to announce it has now agreed with Haleon to extend this arrangement by increasing the product offering and territories under the Agreement to take advantage of the unique and innovative products Wellnex has developed.

Under the extension of the Agreement, during FY24 Wellnex will commence supplying Haleon with the following products for the following new international markets :

- Liquid Paracetamol Soft Gel for the United Kingdom and Ireland (3 SKU's)
- Liquid Paracetamol plus Caffeine Soft Gel for the United Kingdom and Ireland (3 SKU's)
- Liquid Paracetamol plus Ibuprofen Soft Gel for the United Kingdom and United Arab Emirates (2 SKU's)

Haleon is a world-leading consumer healthcare company that owns brands including Panadol, Sensodyne, Voltaren, Polident, Centrum, Otrivin and Advil.



This extension of the Agreement highlights the scale benefits of Wellnex's business model of developing innovative healthcare products and intellectual property (IP) and accelerating distribution via significant partnership arrangements. This model allows Wellnex to supply its innovative product under a trusted brand and enables the Company to secure valuable agreements with leading partners, such as Haleon.

Zack Bozinovski, Director of Wellnex, said: "We are excited to announce that Wellnex has extended its supply agreement with Haleon. This builds on the existing arrangement of supplying our Liquid Paracetamol product for the Australian and New Zealand market which continues to deliver substantial sales for Wellnex. With the expansion into these new international territories and the introduction of two new innovative products we expect to see significant growth in revenue from this arrangement during FY24 and beyond. We're pleased to be able to partner with global leaders such as Haleon who provide significant global distribution opportunities for our products."

This announcement has been authorised for release on the ASX by the Company's Board of Directors.

ENDS

Further Information:

Company:

George Karafotias
Chief Executive Officer
Email: george.k@wellnexlife.com.au
Phone: 03 8399 9419

Investor Relations and Media:

Julia Maguire
Investor Relations Executive
Email: julia@thecapitalnetwork.com.au
Phone: 0289 993 699

About Wellnex Life

Wellnex Life Limited (ASX: WNX) is a consumer healthcare business that specialises in developing and licensing healthcare brands and products to bring to market. Listed in 2021, Wellnex has successfully launched and licensed cutting-edge brands in emerging specialty categories and has established key partnerships and agreements with leading companies in the Australian and global health space. Wellnex is focused on building a portfolio of brands and businesses that can improve the health of consumers, that will ultimately create value for shareholders.

Stay updated

To stay updated with the latest company news and announcements, update your details on the [Wellnex Life investor centre](#).

